





## 2 & 12-PACK COVID-19 RAPID ANTIGEN AT-HOME TEST



INDICAID® OTC is a rapid COVID-19 at-home test that is affordable, accurate, and convenient.

Whether you are focused on workplace wellness, family at-home care, or providing follow-up homecare to patients, using INDICAID® OTC 2 & 12-PACKS for COVID-19 testing is a great way to ensure the safety of families, individuals, and patients while "living life" during this pandemic.



# INDICAID® OTC



#### **2PK & 12PK TEST**

60008-0407-80 (2-PACK) 60008-0407-81 (12-PACK)

OTC 2PK: \$2.75 Per Test (Flat Rate)

• Expiration Dates: April 2024 (+3 Month Extension)

OTC 12PK: \$2.00 Per Test (Flat Rate)

- Expiration Dates: OCT & NOV 2023 (+3 Month Extension)
- Relabeled with FDA Expiration Extension: \$0.65 Per Test
- Need for more 12PK production: \$2.50 Per Test.
- 8 R0001s (12pk PDQ) per case 96 kits/192 tests per case
  - Master Case Dimensions & Weight: 17" x 16" x 11.5" 13.5 lb.
- 32 cases per pallet, 8 cases per layer, 4 layers per pallet
  - o Total: 256 PDQs per pallet. 3,072 kits / 6,144 tests per pallet
  - Pallet Dimensions & Weight: 49" x 40" x 52" 450 lb.



# INDICAID® OTC

## INDICAID one ADVANTAGE

- **EASY** 
  - User friendly testing, no equipment, or training required
- **FAST** 
  - Visual test results are available to read in just 20 minutes
- ACCURATE
  - 81.7% Sensitivity, 99.4% Specificity 93.4% Overall Accuracy

- SIMPLE
  - Intuitive process for self-collected shallow nasal samples
- CONVENIENT
  - Allows patients and consumers to test in the privacy of their own home
- AUTHORIZED
  - US FDA Emergency Use Authorization (EUA) EUA NUMBER: # EUA220152





## **GREAT FOR THE FOLLOWING USES**



#### **PHARMACIES**

Great for patients to take home for family use and safety.



Send patients home with a sufficient self-testing supply for continued monitoring.



Convenient way for staff and workers to test at-home quickly and easily.



Protect seniors and high-risk individuals, using larger quantities allows residents to test regularly.



#### **FAMILIES**

Larger quantities per box provides families the ability to test 2-3 times a week.

#### **BACK TO SCHOOL**

Stay ahead of the germs, and keep your students safe.



Test while on the go, from anywhere... choice of 12-PACK and 2-PACK sizes.

#### LARGE GATHERINGS & EVENTS

Test before and after to protect all those around you.





# ND CA D OTC

#### **CLINICAL PERFORMANCE**

The US FDA has extended their emergency use authorization (EUA) for the INDICAID® COVID-19 Rapid Antigen At-Home Test to cover serial testing for asymptomatic individuals in a recent update. The update extends the use of INDICAID® as a screening test, providing an additional accurate and reliable testing option for schools, workplaces & communities, healthcare providers, and consumers.

- OTC ACCURACY: 81.7% SENSITIVITY
  - 99.4% SPECIFICITY
  - 93.4% OVERALL ACCURACY\*

\*Accuracy may vary given the user, and how well the instructions for use (IFU) are followed.








# INDICAID® OTC


## **INDICAID OTC Rapid Antigen Test Instruction Guide**



Step 1: Gently Swab and Collect: Tilt your headback. Gently insert the swab about 1 inch into one of your nostrils. Rub the swab against the walls of one of your nostrils 4 times in a large circular path. Repeat with your other nostril.



**Step 2:** Insert Swab & Stir: Remove the entire cap. Stir the swab into the buffer solution 20 times. Throw away the swab and screw back the cap.



**Step 3:** Apply Sample: Hold the vial vertically. Squeeze and drip 3 drops of the solution into the circular opening (S) of the test device.



**Step 4:** Read Results: Leave for 20 minutes and read the results. Do not read after 25 minutes.



## INDICAID® ON DISPLAY

**Enhancing Our Retail Presence for You** 



COVID-19 created enormous demand for at-home testing over the past two years, and we continue to see significant demand in the diagnostics market. As the starting point for a pharmacy's diagnostics category growth, proactively merchandising COVID-19 at-home test kits is an important next step. We are excited to announce the INDICAID® Point-of-Purchase display is now available to help retail partners better promote the brand, educate the consumer, and ultimately sell product.

#### Benefits of Using a POS/POP Display

- More eye-catching and visually appealing than product packaging alone
- Clear messaging allows for better opportunity to educate shopper
- QR code directs shopper to INDICAID
   Test-to-Treat powered by Dr. B which allows patients to get virtual treatment for COVID-19
- Boost impulse sales and maximize empty space in your footprint
- Leverage for secondary placements such as pharmacy counter, cash register, and Cold & Flu End Caps

#### **Dimensions & Pricing**


- Includes 12 (twelve) 2-packs of INDICAID COVID-19 Rapid Antiger At-Home Tests
- Dimensions of Display:
   8.0938 in. (W)
   8.4375 in. (H) includes top flag
   6.1250 in. (D)
- (includes cost for 12 (twelve) 2-packs (24 Tests Total):





## **Test-to-Treat**

Have you tested positive? Don't lose valuable treatment time. Prescription antivirals like PAXLOVID™ and Molnupiravir can help reduce symptoms and keep you out of the hospital. Find out if you're eligible for treatment with an online consultation from Dr. B. Medical consultations are only \$15 or you can apply for a no-cost\* option based on financial need.





## Hospitals, Urgent Care & Physician Clinics

Send patients home with a sufficient self-testing supply for continued at-home monitoring.



## Workplace & Employee Wellness

Convenient for your employees to test at-home quickly and easily, with rapid and accurate results.



## Pharmacies & Other Retailers

Help customers get fast, accurate results with at-home, DIY testing.





### **OMICRON EG.5 VARIANT UPDATE**

Phase Scientific continuously monitors emerging variants of the virus that causes COVID-19 and how their mutations may impact the performance of the INDICAID® COVID-19 Rapid Antigen Test.

An independent evaluation by the National Institutes of Health (NIH) RADx Variant Task Force has determined that the INDICAID® test detects the Omicron variant B.1.1.529 and Omicron sub-variants BA.2 (B.1.1.529.2) and BQ.1.1 in live clinical samples. Phase Scientific has also performed in-house analytical testing for the detection of Omicron sub-variant nucleocapsid (N) protein. Limiting dilution studies of recombinant N protein from the Omicron sub-variants listed in the table below demonstrated that the INDICAID® test achieves a similar level of detection compared to that of the original strain of SARS-CoV-2.

Taken together, our in-house testing and the independent evaluation by the RADx VTF suggest that the N protein mutations of currently circulating Omicron sub-variants, including the recently identified EG.5, XBB.1.5, XBB.1.16, BQ.1 and BQ.1.1, are unlikely to impact INDICAID® test performance.

A summary of the expected impact of the various Omicron sub-lineages on the INDICAID® test performance is presented in the table below.

| Omicron Sub-<br>lineage | Expected Impact on<br>INDICAID<br>Performance | Method of Evaluation                            |
|-------------------------|---|---|
| B.1.1.529               | No impact                                     | Independent evaluation by NIH RADx              |
| BA.1 (B.1.1.529.1)      | No impact                                     | In-house wet-testing with recombinant N protein |
| BA.2 (B.1.1.529.2)      | No impact                                     | Independent evaluation by NIH RADx              |
| BA.2.12.1               | No impact                                     | In-house wet-testing with recombinant N protein |
| BA.3                    | No impact                                     | In-house wet-testing with recombinant N protein |
| BA.4                    | No impact                                     | In-house wet-testing with recombinant N protein |
| BA.5                    | No impact                                     | In-house wet-testing with recombinant N protein |
| BQ.1                    | No impact                                     | In-house wet-testing with recombinant N protein |
| BQ.1.1                  | No impact                                     | Independent evaluation by NIH RADx              |
| XBB.1.5                 | No impact                                     | In-house wet-testing with recombinant N protein |
| XBB.1.16                | No impact                                     | In-house wet-testing with recombinant N protein |
| EG.5                    | No impact                                     | In-house wet-testing with recombinant N protein |



### **Rapid Antigen Tests**

### Currently Offering:

- INDICAID COVID-19 Rapid Antigen At-Home Test (Available in 2-pack and 12-pack)
- Retail ready point-of-purchase displays to help generate revenue from secondary placement opportunities
- INDICAID COVID-19 Rapid Antigen PoC Test (Available in 25-pack)

### Rapid Antigen Test Pipeline:

- COVID-19/Flu A&B- PoC & OTC (Q4 2023)
- Sexually Transmitted Diseases
  - Chlamydia antigen tests PoC & OTC (Q3 2024)
- Respiratory Panel
  - COVID, Flu A/B, RSV multiplex antigen selftest (Q4 2024)
- Developing our own and unique licensing opportunities for thyroid, food allergy, drugs of abuse (fentanyl POC)

"Point of Care and OTC Tests"







